Efficacy of Gemcitabine on Intracranial Erlich Tumor and its Determinants
| Autor: | Filatova Lv, Alexander L. Semenov, Denis Baranenko, Vladimir G. Bespalov, Stukov An, Tatjana Y. Semiglazova, Valerij A. Alexandrov, G. S. Kireeva |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Drug Cyclophosphamide media_common.quotation_subject Antineoplastic Agents Pharmacology Blood–brain barrier Deoxycytidine 01 natural sciences Permeability Mice 03 medical and health sciences 0302 clinical medicine Drug Discovery medicine Animals Tissue Distribution Carcinoma Ehrlich Tumor media_common Cisplatin Mice Inbred BALB C Carmustine Dose-Response Relationship Drug Brain Neoplasms 010405 organic chemistry business.industry Therapeutic effect General Medicine Gemcitabine 0104 chemical sciences Dose–response relationship medicine.anatomical_structure Blood-Brain Barrier 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Drug Research. 70:86-90 |
| ISSN: | 2194-9387 2194-9379 |
| Popis: | Gemcitabine is quite effective in the treatment of brain tumors, although this drug has a limited ability to overcome the blood-brain barrier (BBB). Aim of study is to assess the therapeutic efficacy of gemcitabine and other drugs with different permeability of BBB in the model of intracranial tumor. The therapeutic activity of gemcitabine, carmustine, cyclophosphamide and cisplatin was studied in mice with intracranially implanted Ehrlich tumor, and also gemcitabine in various doses - with intramuscularly implanted tumor. On intracranial tumor model gemcitabine (25 mg/kg) increased the life span (ILS) by 60−89% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|